Rucaparib maintenance appears safe and effective for patients with platinum-sensitive, advanced pancreatic cancer and BRCA1/2 or PALB2 variants, according to research published in the Journal of Clinical Oncology.
Researchers conducted a phase 2 trial (ClinicalTrials.gov Identifier: NCT03140670) of rucaparib maintenance in 46 patients with advanced pancreatic cancer who had germline or somatic pathogenic variants in BRCA1, BRCA2, or PALB2. Read more . . .